-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Classical Hodgkin’s lymphoma (cHL) is characterized by the rare malignant Hodgkin’s lymphoma RS (HRS) cells are surrounded by extensive inflammation and immune cell infiltration, such as T cells, macrophages, neutrophils and B cells
Lymphoma Immune Tumor Immune
Tislelizumab is an anti-programmed death protein 1 (anti-PD-1) monoclonal antibody specifically designed to reduce the binding of PD-1 to Fcγ receptors (FcγR)
This article reports the results of a phase II clinical trial of Tislelizumab for the treatment of 70 patients with relapsed/refractory classic Hodgkin’s lymphoma and extended follow-up for 3 years
stem cell
The overall progression-free survival rate of the tested patients
The overall progression-free survival rate of the tested patientsThe median follow-up was 33.
The overall remission rate was 87.
Progression-free survival rate of patients with or without a history of autologous stem cell transplantation
Progression-free survival rate of patients with or without a history of autologous stem cell transplantation97.
Related biomarker analysis showed that FcγRI-expressing macrophages had no significant effect on the remission rate and progression-free survival of Tislelizumab treatment
In summary, through extended follow-up, the study confirmed that Tislelizumab has long-term survival benefits and good safety in patients with relapsed/refractory cHL
Tislelizumab has long-term survival benefits and good safety in patients with relapsed/refractory cHL.
Original source:
Song Yuqin,Gao Quanli,Zhang Huilai et al.
Tislelizumab for relapsed / refractory classical Hodgkin lymphoma : 3-year follow-up and correlative biomarker analysis
in this message